{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T22:02:19Z","timestamp":1779746539563,"version":"3.53.1"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,25]]},"DOI":"10.7759\/cureus.109633","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T21:06:07Z","timestamp":1779743167000},"source":"Crossref","is-referenced-by-count":0,"title":["Immune Checkpoint Inhibitor-Induced Hypophysitis Presenting as Severe Hyponatremia: A Nephrology Perspective on Avoiding the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) Pitfall"],"prefix":"10.7759","author":[{"given":"Said","family":"Al Zein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa R","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al.. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:173-82. 10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye ES","year":"2022","unstructured":"Husebye ES, Castinetti F, Criseno S, et al.. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022, 187:G1-G21. 10.1530\/EJE-22-0689","journal-title":"Eur J Endocrinol"},{"key":"ref3","article-title":"Immune checkpoint inhibitors related endocrine adverse events","author":"Elshimy G","year":"2022","unstructured":"Elshimy G, Gandhi A, Guo R, et al.. Immune checkpoint inhibitors related endocrine adverse events. Endotext. 2022,","journal-title":"Endotext"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje AT","year":"2014","unstructured":"Faje AT, Sullivan R, Lawrence D, et al.. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014, 99:4078-85. 10.1210\/jc.2014-2306","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/20420188221136755","article-title":"Hyponatraemia in patients on immune checkpoint inhibitors","volume":"13","author":"Paschou SA","year":"2022","unstructured":"Paschou SA, Kassi E, Psaltopoulou T. Hyponatraemia in patients on immune checkpoint inhibitors. Ther Adv Endocrinol Metab. 2022, 13:20420188221136755. 10.1177\/20420188221136755","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/493724-immune-checkpoint-inhibitor-induced-hypophysitis-presenting-as-severe-hyponatremia-a-nephrology-perspective-on-avoiding-the-syndrome-of-inappropriate-antidiuretic-hormone-siadh-pitfall","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T21:06:08Z","timestamp":1779743168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/493724-immune-checkpoint-inhibitor-induced-hypophysitis-presenting-as-severe-hyponatremia-a-nephrology-perspective-on-avoiding-the-syndrome-of-inappropriate-antidiuretic-hormone-siadh-pitfall"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":6,"URL":"https:\/\/doi.org\/10.7759\/cureus.109633","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,25]]}}}